VaccineCOVID-19Research activityLiving reviewScoping reviewObjective:This scoping review will summarize COVID-19 vaccine research activities and describe the extent,range,and nature of evidence in the research of COVID-19 vaccines.Methods:Following Arksey and O'Malley's framework and the methodological...
ALL ARTICLES INCoronavirus and COVID-19: All Articles From the latest COVID-19 news, treatment and vaccine developments, inspiring patient stories, to expert advice, we're here to help you live your healthiest life every day and through this pandemic.All...
These vaccines have saved innumerable lives and contributed to partial control of the COVID-19 pandemic. Most of the vaccines approved for clinical use exhibit satisfactory initial protection rates against corresponding strains. However, vaccine protection declines over time, with almost all vaccines ...
Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671–681 (2021). Article CAS Google Scholar Widge, A. T. et al. Durability of responses ...
Since the beginning of the pandemic, we have played a significant role in addressing the devastating impact of COVID-19. The development, manufacture and supply of our COVID-19 vaccine was a principal achievement within our response to the COVID-19 pandemic. In partnership, we built over 25...
Recently, COVID-19 vaccine hesitancy has been a subject of intense global interest. It is well known that the accelerated speed of the development as well as the fact that the vaccine is new has caused fear of its unknown safety and long-term side effects. The duration of protection of ...
Three requirements guide this vaccine effort—speed, manufacture and deployment at scale, and global access. At the time of writing this review, many drug companies, biotechnology firms, university research groups such as Pfizer-BioNTech, AstraZeneca and The University of Oxford, Serum Institute of ...
COVID-19vaccinepandemicregulationintellectual propertyhealth and safetyuniversal accessWill the regulation of a vaccine for COVID-19 be left in the hands of health standards administrators and research conventions or will an alliance of political
In the eleven months elapsed since the identification of the SARS-CoV-2 virus and its genome, an exceptional effort by the scientific community has led to the development of over 300 vaccine projects. Over 40 are now undergoing clinical evaluation, ten o
Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and ...